Synthesis, molecular docking, molecular dynamics, pharmacokinetics prediction and bioassay of N-(phenylcarbamothioyl)-4- chlorobenzamide as anti-breast cancer candidate

Kesuma, Dini and Yuniarta, Tegar Achsendo and Suherto, Alfiani Damayanti and Putra, Galih Satrio and Sutrisno, Sutrisno and Anwari, Farida (2024) Synthesis, molecular docking, molecular dynamics, pharmacokinetics prediction and bioassay of N-(phenylcarbamothioyl)-4- chlorobenzamide as anti-breast cancer candidate. Journal of Pharmacy & Pharmacognosy Research, 13 (2). pp. 551-564. ISSN 0719-4250

PDF Dini Kesuma_Synthesis, molecular docking.pdf Download (1MB)

Abstract

Context: Breast cancer ranks as the leading cause of mortality among women in Indonesia. Thiourea is a compound containing sulfur atom and nitrogen in which its chemical structure resembles urea compound, which has been applied as an anticancer, such as hydroxyurea, nitrosourea, 5-fluorouracil, and sorafenib. Aims: To develop anticancer candidates as a new compound of thiourea derivative, N-(phenylcarbamothioyl)-4-chloro-benzamide (4-Cl-PCTB). Methods: The compound was synthesized from phenylthiourea and 4-chloro-benzoyl chloride by applying nucleophilic acyl substitution reactivity. The compound resulting from synthesis was examined for its purity and structure identification by using FTIR, 1H-NMR,13C-NMR, and MS. In silico tests included molecular docking using Molexus software, molecular dynamics simulation using Desmond and MOE software, and pharmacokinetics prediction using SCFbio, pkCSM, and Swiss ADME. Anticancer activity through cytotoxic test was done using the MTT method in T47D cancer cells and Vero normal cells. Results: The 4-Cl-PCTB compound was obtained from the synthesis. The results of the molecular docking and molecular dynamics simulation on the checkpoint kinase 1 receptor (2YWP) showed a plant score of -67.19 kcal/mol, which was better than the native ligand and the standard reference hydroxyurea. The molecular dynamics simulation results indicated that the 4-Cl-PCTB compound exhibited better bond stability compared to hydroxyurea. Pharmacokinetic predictions for 4-Cl-PCTB showed good GIT absorption, classifying it under BCS Class I, with a low volume of distribution, no BBB penetration, a half-life of 3 hours, and no hepatotoxicity. The results of the cytotoxic test: IC50 T47D cells = 0.44 mM, Vero cells = 76.10 mM, hydroxyurea = 4.58 mM. SI value = 173.35 (SI >10). Conclusions: 4-Cl-PCTB is possible to be an anticancer candidate drug better than hydroxyurea.

Item Type:	Article
Uncontrolled Keywords:	anticancer; molecular docking; molecular dynamics; MTT assay; synthesis; thiourea derivative
Subjects:	R Medicine > RS Pharmacy and materia medica
Divisions:	Faculty of Pharmacy > Department of Pharmacy
Depositing User:	Ester Sri W. 196039
Date Deposited:	26 Nov 2024 05:16
Last Modified:	26 Nov 2024 05:16
URI:	http://repository.ubaya.ac.id/id/eprint/47429

Actions (login required)

View Item